Shares of Alexion Pharmaceuticals were up nearly 4 percent in premarket trading after the company announced a collaboration with Dicerna Pharmaceuticals on the development of an RNAi therapeutic for the treatment of complement-mediated diseases.
Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.
Carlsbad, Calif.-based Ionis Pharmaceuticals announced that GlaxoSmithKline declined its options on both inotersen and IONIS-FB-Lrx, which gives Ionis back control of those rights.